creased by 36%, which is likely a partial result of the retrospective data described above ( Figure 1 ). As in previous years, most of the centers (84%) performed fewer than 5 transplant procedures annually; however, for the first time Num 0 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 There are geographic differences in the age distribution of pediatric lung transplant recipients: in Europe, 82% of the procedures between January 2000 and June 2010 were performed in recipients aged Ն 12 years compared with 65% in North America. In contrast, 4% of the reported lung transplant procedures in this period in Europe were performed in recipients aged Յ 5 years compared with 15% in North America ( Figure 6 ).
In the period from January 1986 to June 2010, 64% of the pediatric lung transplant recipients received pediatric donor organs (aged Ͻ18 years). Only 6% received organs from donors aged Ն50 years ( Figure 7) . Geographic differences in donor age distribution are noticeable: in Europe, 45% of transplanted organs come from pediatric donors compared with 64% in North America. The proportions in regions outside Europe and North America were similar to those in Europe (Figure 8 ). In the last 5 years, only 1 pediatric lung transplant procedure from a living donor was reported to the Registry (Figure 9 ).
Similar to previous reports, 1-3 the most common underlying diagnosis for children and adolescents (aged Ͻ18 years) who undergo lung transplantation is cystic fibrosis (CF). However, differences in age groups can be observed. In children aged Ն 6 years, CF was the most common diagnosis from January 1990 to June 2010 (Table 1) . In children aged 5 years and younger, the most common indications were idiopathic pulmonary arterial hypertension, idiopathic pulmonary fibrosis, congenital heart disease, and surfactant protein B deficiency ( Table 1 ). The overall distribution of indications has not changed notably compared with previous reports. [1] [2] [3] However, regional differences exist in the diagnosis distribution: 55% of transplant procedures in North America were undertaken in pediatric recipients with CF compared with 75% in Europe (Figure 10) . Interestingly, the diagnosis of CF accounted for 70% in Europe in last year's report. The increase in the number of transplant procedures for CF in Europe could partly be explained by the above-mentioned retrospective data entry.
Immunosuppressive therapy
The use of induction therapy increased further compared with previous reports. [1] [2] [3] Between January 2001 and June 2010, induction therapy, consisting of anti-lymphocyte globulin, anti-thymocyte globulin, and interleukin-2 receptor antagonist therapy, was used in 60% of the procedures ( Figure 11) ; a decade ago, this was less than 50%. [1] [2] [3] No significant 5-year post-transplant survival difference was noted between recipients who did and did not receive induction therapy (Figure 12 ).
The use of maintenance immunosuppression is displayed in Figure 13 . Tacrolimus use increased further compared with cyclosporine. At the 1-year follow-up, 78% of pediatric recipients received tacrolimus compared with 22% who 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 was used in 55% of recipients at the 1-year follow-up and in 47% at the 5-year follow-up, (Figure 14 ).
Outcomes
Survival after pediatric lung transplantation continues to be comparable with that reported in adult lung transplant recipients. We define the transplant half-life as the estimated time at which 50% of all recipients have died. In the period from January 1990 to June 2009, the half-life of adult recipients was 5.4 years compared with 5.5 years in pediatric recipients (Figure 15 ), although there seems to be better longer-term survival in pediatric patients. The 5-year survival of pediatric lung transplant recipients between January 1990 and June 2009 was 51%. For pediatric recipients who received allografts in the new era between 2002 and June 2009, 5-year survival was 53% and 7-year survival was 45% (Figure 16 ). In contrast to the previous year's report, the difference is not statistically significant when survival is analyzed by era; this may be because survival for older cohorts is revised upward compared with previous reports after the retrospective data entry, as described above. Kaplan-Meier survival analysis by recipient age group shows a significantly better survival of recipients aged 1 to 11 years compared with recipients aged 12 to 17 years ( Figure 17 ). Recipients younger than 1 year have the worst early post-transplant survival within the 3 age groups (Ͻ1 year vs 1-11 years vs 12-17 years). Nevertheless, in younger patients surviving at least 1 year after transplant, long-term outcome is comparable with that of other pediatric age groups (Figure 18 ). Survival analyzed by procedure type is significantly worse for single-lung transplant procedures compared with bilateral lung transplant procedures; however, the number of pediatric single-lung transplant procedures is relatively small (Figure 19 ).
Causes of death
In the first year after lung transplantation, infection (noncytomegalovirus [CMV]) and graft failure remained the 2 leading causes of death (Figure 20) . Beyond the first year after transplantation, bronchiolitis obliterans syndrome (BOS), graft failure, and non-CMV infection were the leading causes of death. Further details regarding causes of death and relative incidences of leading causes of death are displayed in Figure 20 and Table 2 . Details about causes of death labeled as "other" were published in the 2008 ISHLT Registry Report and are not presented again this year because the data have not changed considerably. 
Complications and morbidities
Hypertension, renal impairment, diabetes mellitus, and BOS remain the most common comorbidities after pediatric lung transplantation, and all of these increase in prevalence with time after transplantation. Detailed figures of cumulative prevalence of morbidities within 1 and 5 years after transplantation are reported in Tables 3 and 4 , respectively, and are similar to the figures presented in last year's report. 3 Severe renal impairment, defined as creatinine Ͼ 2.5 mg/dl (221 mol/liter), dialysis, or renal transplant, develops in 11% of pediatric lung transplant recipients by 5 years after transplantation and in 17% by 7 years ( Figure 21) ; once again, figures were identical with last year's report. 3 By 5 years after transplantation, malignancies have developed in 14% of pediatric recipients, virtually all of which are lymphoproliferative diseases. By 9 years, the cumulative incidence of malignancies increases to 23%, comprising mostly lymphoproliferative disorders but also 2% skin cancer (Figure 22 ). BOS, the second most common morbidity within 5 years after transplantation, was reported in 56% of pediatric lung transplant recipients. 3 For the first time, we analyzed freedom from BOS for pediatric lung recipients, stratified by age group and diagnosis. BOS was reported less frequently in younger surviving lung recipients; that is, in 31% of the recipients aged Ͻ 1 year compared with 44% in recipients aged 1 to 11 years and 54% of recipients aged Ն 12 years by 4 years after transplantation (Figure 23 ). When stratified by diagnosis (CF vs idiopathic pulmonary artery hypertension), cumulative incidence of BOS by 5 years after transplantation was similar between the 2 groups (Figure 24) .
The functional status of surviving pediatric lung transplant recipients is very good, with 86% of children having no physician-reported activity limitation even 5 years after (Figure 25 ). Further details regarding functional status and re-hospitalization needs of surviving recipients are displayed online (www.ishlt.org/registries).
Lung retransplantation
In the interval from January 1994 to June 2010, 105 retransplant procedures were reported to the ISHLT Registry. Retransplantation was performed for obliterative bronchiolitis (OB) in 50 patients and for indications other than OB in 51. Most of the retransplantations occurred in recipients aged Ն 12 years. In recipients with OB, 36 of 50 procedures (72%) were performed in recipients aged Ն 12 years. Retransplantations for indications other than OB were performed in recipients aged Ն12 years in 38 of 51 cases (75%; Table 1 ).
Regional differences in lung retransplantation activity exist. In Europe, retransplantation was the indication for transplantation in only 3% of the procedures, compared with 7% in North America (Figure 10 ). Survival after lung retransplantation was worse compared with primary lung transplantation if all indications for retransplantation were taken together and results were not stratified by inter-transplant interval (the time between the primary and the retrans- plant procedure). For pediatric retransplant procedures performed between January 1994 and June 2009, survival was 63% at 1 year, 50% at 3 years and 38% at 5 years Figure  26 ). However, when pediatric lung retransplant procedures between January 1988 and June 2009 were stratified by inter-transplant interval (30 at Ͻ 1 year vs 59 at Ն 1 year), the 1-year survival was 39% and 62%, respectively ( Figure  27 ). It is important to note that the analyses included livingdonor transplants and only patients who were aged Ͻ 18 years at the time of the retransplant procedure. Interestingly, when pediatric re-transplant procedures were stratified by diagnosis-51 OB vs 57 non-OBsurvival after retransplantation was similar between both sub-groups (Figure 28 ). Owing to the small number of cases, a survival analysis after pediatric lung retransplantation by era was not feasible. However, this will most likely change in the future with the increasing number of retransplant procedures performed in pediatric recipients worldwide. In summary, this ISHLT Registry pediatric lung transplantation report shows that the number of centers reporting pediatric transplants to the Registry and the annual number of pediatric lung transplant procedures are constantly increasing, with a total of 127 lung transplant procedures in 2009. Overall, survival after pediatric lung transplantation is improving, with a half-life of more than 5 years for procedures performed in the last 20 years, comparable to results achieved in adult recipients.
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